Open Label, Multiple-Dose Study to Evaluate the Antiviral Activity, Safety, Tolerability and Pharmacokinetics of BMS-824393 in Treatment Naive Subjects Infected With Hepatitis C Virus Genotype 1.
Phase of Trial: Phase I
Latest Information Update: 06 Jan 2011
At a glance
- Drugs BMS 824393 (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 02 Oct 2010 Results will be presented at the 61st annual meeting of the American Association for the Study of Liver Diseases (AASLD), according to a Bristol-Myers Squibb media release.
- 11 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 14 Jun 2010 Planned number of patients changed from 40 to 50 as reported by ClinicalTrials.gov.